Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$295.0 - $350.58 $2.62 Million - $3.11 Million
-8,876 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$268.3 - $380.31 $2.37 Million - $3.36 Million
8,825 Added 17303.92%
8,876 $2.44 Million
Q4 2020

Feb 08, 2021

SELL
$248.13 - $308.36 $2,729 - $3,391
-11 Reduced 17.74%
51 $15,000
Q3 2020

Nov 13, 2020

SELL
$215.51 - $272.51 $4,310 - $5,450
-20 Reduced 24.39%
62 $16,000
Q4 2019

Feb 07, 2020

SELL
$106.59 - $164.21 $1.5 Million - $2.3 Million
-14,029 Reduced 99.42%
82 $13,000
Q3 2019

Nov 13, 2019

SELL
$113.31 - $150.51 $2.34 Million - $3.11 Million
-20,639 Reduced 59.39%
14,111 $1.61 Million
Q2 2019

Aug 13, 2019

SELL
$115.0 - $141.58 $172,500 - $212,370
-1,500 Reduced 4.14%
34,750 $4.92 Million
Q1 2019

May 13, 2019

BUY
$98.85 - $134.59 $3.58 Million - $4.88 Million
36,250 New
36,250 $4.53 Million
Q1 2018

May 14, 2018

SELL
$56.95 - $85.19 $5.34 Million - $7.99 Million
-93,812 Closed
0 $0
Q3 2017

Nov 13, 2017

SELL
$19.81 - $22.61 $1.11 Million - $1.27 Million
-56,188 Reduced 37.46%
93,812 $2.11 Million
Q2 2017

Aug 29, 2017

BUY
N/A
150,000
150,000 $3.18 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Fil LTD Portfolio

Follow Fil LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fil LTD with notifications on news.